Hostname: page-component-7b7567c8c-2jgqx Total loading time: 0 Render date: 2026-11-19T18:39:16.987Z Has data issue: false hasContentIssue false

Antimicrobial use before and during COVID-19: data from 108 Veterans Affairs medical centers

Published online by Cambridge University Press:  07 August 2024

Matthew Bidwell Goetz*
Affiliation:
VA Greater Los Angeles Healthcare System and David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Tina Willson
Affiliation:
VA Salt Lake Informatics, Decision-Enhancement, and Analytic Sciences (IDEAS) Center, VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, USA
Michael A. Rubin
Affiliation:
VA Salt Lake Informatics, Decision-Enhancement, and Analytic Sciences (IDEAS) Center, VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, USA
Vanessa W. Stevens
Affiliation:
VA Salt Lake Informatics, Decision-Enhancement, and Analytic Sciences (IDEAS) Center, VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, USA
Christopher J. Graber
Affiliation:
VA Greater Los Angeles Healthcare System and David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
*
Corresponding author: Matthew Bidwell Goetz; Email: Matthew.Goetz@va.gov

Abstract

Objective:

Inpatient antibiotic use increased during the early phases of the COVID-19 pandemic. We sought to determine whether these changes persisted in persons with and without COVID-19 infection.

Design:

Retrospective cohort analysis.

Setting:

108 Veterans Affairs (VA) facilities.

Patients:

Persons receiving acute inpatient care from January 2016 to October 2022.

Methods:

Data on antibacterial use, patient days present, and COVID-19 care were extracted from the VA Corporate Data Warehouse. Days of therapy (DOT) per 1000 days present (DP) were calculated and stratified by Centers for Disease Control and Prevention-defined antibiotic classes.

Results:

Antibiotic use increased from 534 DOT/1000 DP in 11/2019–2/2020 to 588 DOT/1000 DP in 3/2020–4/2020. Subsequently, antibiotic use decreased such that total DOT/1000 DP was 2% less in 2020 as a whole than in 2019. Driven by treatment for community acquired pneumonia, antibiotic use was 30% higher in persons with COVID-19 than in uninfected persons in 3/2020–4/2020, but only 4% higher for the remainder of 2020. In 2022 system-wide antibiotic use was 9% less in persons with COVID-19; however, antibiotic use remained higher in persons with COVID-19 in 25% of facilities.

Discussion:

Although antibiotic use increased during the early phases of the COVID-19 pandemic, overall use subsequently decreased to below previous baseline levels and, in 2022, was less in persons with COVID-19 than in persons without COVID-19. However, further work needs to be done to address variances across facilities and to determine whether current levels of antibiotic use in persons with COVID-19 are justified.

Information

Type
Original Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is a work of the US Government and is not subject to copyright protection within the United States. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America.
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© US Government, 2024
Figure 0

Table 1.Patient characteristics 1/1/2016–10/31/2022

Figure 1

Figure 1.The bars represent total monthly antibiotic use, shown as Days of Therapy per 1000 Days present, for patients hospitalized on acute care and intensive care units at all included VA facilities. The solid, dashed and dotted lines represent the number of monthly admissions for all patients and patients without and with acute COVID-19, respectively.

Figure 2

Figure 2.In each of the panels, the dotted and solid lines represent monthly antibiotic use by CDC NHSN antibiotic class, for hospitalized patients with and without acute COVID-19.

Figure 3

Table 2.Mean antibiotic use (DOT/1,000 DP) versus patient-level COVID-19 status

Figure 4

Table 3.Median (IQR) facility-level antibiotic use versus patient-level COVID-19 status

Figure 5

Figure 3.Panel A shows the interquartile range (25%–75%) of facility-level antibiotic use at all included VA facilities. Panel B shows the interquartile range of the facility-specific difference between antibiotic use in persons with and without acute COVID-19. Values greater than zero represent instances where antibiotic use was greater in persons with COVID-19 than in persons without COVID-19.